NEW YORK (GenomeWeb News) — Invitrogen said Tuesday that it has inked two new agreements, one with Tecan and another with BMG Labtech, to study and validate its reagents with the companies’ microplate instruments.
Under the terms of both of the agreements, announced separately, Invitrogen will work with the companies to develop and promote joint applications to market to pharmaceutical companies.
In the agreement with Tecan, Invitrogen will validate the compatibility of its reagents with Tecan’s microplate detection tools.
Specifically, the companies will validate Invitrogen’s drug discovery reagents on the Tecan Infinite series readers, and on assay systems for key target classes, including Invitrogen’s LanthaScreen TR-FRET for protein kinases, the GeneBLAzer reporter-gene technology for G protein-coupled receptors, and the Adapta assay system for lipid kinases.
Under the BMG Labtech agreement, Invitrogen will test its reagents with certain of the company’s readers, as well as its PHERAstar and Omega series instruments.
This collaboration will also focus on Invitrogen’s LanthaScreen TR-FRET, GeneBLAzer, and Adapta assays, as well as the PolarScreen FP technology for nuclear receptors.